Skip to content

AYTU BIOPHARMA, INC: 10-K filed 2020-10-06

What AYTU BIOPHARMA, INC reported in its annual report filed 2020-10-06 (fiscal FY 2020): 43 published measures, 86 facts as tagged in accession 0001654954-20-010891.

This filing

Form
10-K (annual report)
Filed
2020-10-06
Fiscal period
fiscal FY 2020
Accession
0001654954-20-010891 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AYTU BIOPHARMA, INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-06-30152,836,330USD
At 2019-06-3034,721,391USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-06-3057,821,034USD
At 2019-06-3027,633,573USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-06-3095,015,296USD
At 2019-06-307,087,818USD
At 2018-06-3013,424,505USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-06-3048,081,715USD
At 2019-06-3011,044,227USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-07-01 to 2020-06-30-13,620,679USD366
2018-07-01 to 2019-06-30-27,131,908USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-07-01 to 2020-06-30-28,373,887USD366
2018-07-01 to 2019-06-30-13,831,377USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-07-01 to 2020-06-300USD366
2018-07-01 to 2019-06-3059,848USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2019-07-01 to 2020-06-3027,632,080USD366
2018-07-01 to 2019-06-307,320,357USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-07-01 to 2020-06-3071,068,739USD366
2018-07-01 to 2019-06-3019,075,062USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-07-01 to 2020-06-30-5,655,772USD366
2018-07-01 to 2019-06-30-1,061,985USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-06-30-120,010,179USD
At 2019-06-30-106,389,500USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2019-07-01 to 2020-06-300USD366
2018-07-01 to 2019-06-300USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-06-30258,516USD
At 2019-06-30203,733USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-07-01 to 2020-06-301,079,311USD366
2018-07-01 to 2019-06-301,022,202USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-07-01 to 2020-06-30-21,130,546USD366
2018-07-01 to 2019-06-30-16,846,637USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-06-3074,965,772USD
At 2019-06-3015,432,864USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-07-01 to 2020-06-302,606,487USD366
2018-07-01 to 2019-06-30535,500USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-06-3028,306,581USD
At 2019-06-305,372,576USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-06-3011,824,560USD
At 2019-06-302,133,522USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2020-06-3028,090,407USD
At 2019-06-300USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2020-06-3048,855,000USD
At 2019-06-3019,083,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2020-06-305,175,924USD
At 2019-06-301,740,787USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-07-01 to 2020-06-3048,762,626USD366
2018-07-01 to 2019-06-3024,166,994USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2020-06-309,999,441USD
At 2019-06-301,440,069USD

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2019-07-01 to 2020-06-307,553,031USD366
2018-07-01 to 2019-06-302,202,041USD365

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2019-07-01 to 2020-06-3034,802,432USD366
2018-07-01 to 2019-06-3018,887,783USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-07-01 to 2020-06-301,721,419USD366
2018-07-01 to 2019-06-30589,072USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-06-30125,837,357shares
At 2019-06-3017,538,071shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-06-30215,012,891USD
At 2019-06-30113,475,205USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-06-30634,093USD
At 2019-06-300USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-06-301,026,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-06-30484,000USD
At 2019-06-30396,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-06-3016,586,847USD
At 2019-06-3018,861,983USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-06-304,731,866USD
At 2019-06-300USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-06-307,849,855USD
At 2019-06-301,311,488USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-06-305,715,089USD
At 2019-06-30957,781USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2020-06-30339,336USD
At 2019-06-300USD

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2019-07-01 to 2020-06-306,245,827USD366
2018-07-01 to 2019-06-302,727,067USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2019-07-01 to 2020-06-304,490,466USD366
2018-07-01 to 2019-06-302,136,255USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2019-07-01 to 2020-06-307,509,867USD366
2018-07-01 to 2019-06-30-10,285,271USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2019-07-01 to 2020-06-301,040,276USD366
2018-07-01 to 2019-06-300USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2019-07-01 to 2020-06-303,560,860USD366
2018-07-01 to 2019-06-301,162,005USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2019-07-01 to 2020-06-306,950,624USD366
2018-07-01 to 2019-06-30101,096USD365

Inspect the source

Entity
AYTU BIOPHARMA, INC / CIK 0001385818
Captured
2026-09-20T07:58:53.461Z
SEC response SHA-256
3b664ab8156647d48cbdda6c8eb0b5f1ac4147c50f45c9bb53fa74b58565a69b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385818.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))